Syantra is a precision biotechnology company that is revolutionizing cancer detection and treatment through its innovative blood-based testing platform. Central to its offerings is the Syantra DX™ Breast Cancer test, a minimally invasive blood test designed to detect early-stage breast cancer signals with high accuracy. This test utilizes a proprietary platform that measures changes in the immune system and other systemic factors associated with the presence of cancer. By analyzing mRNA biomarkers from a small blood sample (2.5 ml), Syantra can provide a cost-effective and efficient means of identifying individuals who may have breast cancer, thereby facilitating timely intervention and treatment.

The technology behind Syantra's testing platform incorporates advanced methodologies, including a custom real-time PCR process and machine learning algorithms for data interpretation. This combination allows for precise measurement of gene expression biomarkers, which are critical for determining the presence or absence of disease. Syantra's commitment to innovation is further exemplified by its recent partnership with Limmi, a technology company focused on AI-driven insights for disease detection. Together, they aim to enhance the capabilities of Syantra's platform, ultimately improving early cancer detection and patient outcomes. With ongoing clinical studies and a focus on expanding its product offerings, Syantra is poised to make significant contributions to the field of oncology.

Canada

Syantra Inc. is a precision healthcare company changing the way cancer is detected and treated, starting with breast cancer.

Learn about Syantra DX | Breast Cancer. A blood test for breast cancer screening that's easy, convenient and accurate.

Syantra

Company Details